About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
ASH 2019 Update on Phase II Study on Obinutuzumab + Lenalidomide in Follicular Lymphoma: Regimen with Favorable OS/PFS Efficacy and Safety Profile
By
Loretta Nastoupil
18 Videos
650 views
December 31, 2019
0 Comments
Login to view comments.
Click here to Login
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Related Content
AUTOPLAY
ON
13:56
SOHO 2023 Eleventh Annual Meeting
Follicular Lymphoma Management: What Is the New Order?
Feat.
B. Kahl
27:51
Louisville Hematology Highlights
Summary of Recent Advances in Follicular Lymphoma
Feat.
S. Gaballa
24:44
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignan…
Feat.
R. Birhiray
27:49
MyCancerHaven
Overview of the Diagnosis and Treatment of Follicular Lymphoma
Feat.
R. Vij,
T. Fehniger
15:08
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Sequencing Therapy in Indolent Lymphoma - Treatment Choic…
Feat.
L. Nastoupil
17:19
SOHO Turkey 2023
SOHO Turkey 2023: How I Treat Follicular Lymphoma
Feat.
J. Lister
15:11
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies
Lymphoma Bispecific Antibody Therapy and Management of CRS
Feat.
D. Land,
M. Hughes
11:12
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 Next Questions: Indolent B-Cell Lymphoma
Feat.
L. Nastoupil
09:10
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Acalabrutinib Added to Lenalidomide & R…
Feat.
P. Strati
36:10
University of Colorado Division of Hematology
2023 Denver ASH Review: Updates in CLL and Lymphoma
Feat.
A. Major
14:36
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
The Latest Data on New Therapies in FL and MZL
Feat.
J. Carter
38:55
Indy Hematology Review
Managing Indolent and Mantle Cell Lymphomas With Targeted and Cellul…
Feat.
G. Salles
06:03
Yale Cancer Center
Yale School of Medicine Approach to Lymphadenopathy: Which Patients …
Feat.
I. Isufi
17:41
5th SOHO Italy Annual Conference
SOHO Italy 2023: How I Manage Follicular, Marginal Zone and Mantle C…
Feat.
S. Luminari
15:32
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Current Clinical Managment of Follicular Lymphoma
Feat.
B. Ferhanoğlu
02:26
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Obinutuzumab, Lenalidomide, and Venetoclax …
Feat.
C. Cheah
15:53
SOHO Brazil 2023
2023 SOHO® Brazil: "Treating First and Second Line Follicular L…
Feat.
J. Alderuccio
22:14
MyCancerHaven
Experts Discuss Highlights in Lymphoma From ASCO® 2023
Feat.
R. Vij,
D. Russler-Germain
21:17
Yale Cancer Center
ASH 2022 Highlights: Follicular and Indolent NHL
Feat.
F. Montanari
20:06
Yale Cancer Center
Managing Suspicious Lymphadenopathy After URI - Malignancy Considera…
Feat.
P. Alam,
F. Montanari
